Physical symptom burden in patients with desmoid‐type fibromatosis and its impact on health‐related quality of life and healthcare use
暂无分享,去创建一个
Robin L. Jones | S. Sleijfer | O. Husson | J. Bonenkamp | W. V. van Houdt | E. Lidington | B. D. de Rooij | D. Grünhagen | Anne-Rose W Schut | M. Timbergen | S. Gennatas | W. V. D. van der Graaf | C. Verhoef | Leanne E de Bruin
[1] M. Gounder,et al. 1488MO Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT) , 2022, Annals of Oncology.
[2] R. Riedel,et al. LBA2 DeFi: A phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT) , 2022, Annals of Oncology.
[3] Robin L. Jones,et al. Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes , 2022, Cancers.
[4] Robin L. Jones,et al. Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis , 2022, Cancers.
[5] Robin L. Jones,et al. The Evaluation of Health-Related Quality of Life Issues Experienced by Patients with Desmoid-Type Fibromatosis (The QUALIFIED Study)—A Protocol for an International Cohort Study , 2021, Cancers.
[6] S. Sleijfer,et al. Assessing the Desmoid-Type Fibromatosis Patients' Voice: Comparison of Health-Related Quality of Life Experiences from Patients of Two Countries , 2020, Sarcoma.
[7] Robin L. Jones,et al. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. , 2020, European journal of cancer.
[8] Peter Jeffrey Jordan,et al. Common method bias in applied settings: The dilemma of researching in organizations , 2020, Australian Journal of Management.
[9] Robin L. Jones,et al. Outcome of Primary Desmoid Tumors at All Anatomic Locations Initially Managed with Active Surveillance , 2019, Annals of Surgical Oncology.
[10] P. Fayers,et al. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. , 2019, European journal of cancer.
[11] D. Boll,et al. Illness perceptions are associated with higher health care use in survivors of endometrial cancer—a study from the population-based PROFILES registry , 2018, Supportive Care in Cancer.
[12] L. V. van de Poll-Franse,et al. Cancer survivors not participating in observational patient-reported outcome studies have a lower survival compared to participants: the population-based PROFILES registry , 2018, Quality of Life Research.
[13] Robin L. Jones,et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? , 2018, Supportive Care in Cancer.
[14] S. Sleijfer,et al. Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study , 2018, Quality of Life Research.
[15] L. Traeger,et al. The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer , 2017, Cancer.
[16] J. Blay,et al. Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. , 2017, European journal of cancer.
[17] J. Blay,et al. Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. , 2016, European journal of cancer.
[18] Helen Skerman,et al. Latent Class Analysis Reveals Distinct Subgroups of Patients Based on Symptom Occurrence and Demographic and Clinical Characteristics. , 2015, Journal of pain and symptom management.
[19] M. D. den Bakker,et al. Time Trends in the Incidence and Treatment of Extra-Abdominal and Abdominal Aggressive Fibromatosis: A Population-Based Study , 2015, Annals of surgical oncology.
[20] Philippe Rigaux,et al. Pain burden in desmoid tumor patients: a survey of the French Advocacy Group SOS Desmoid. , 2015, Bulletin du cancer.
[21] S. Bonvalot,et al. Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought , 2013, Annals of Surgical Oncology.
[22] G. Rodin,et al. The relationship between depression and physical symptom burden in advanced cancer , 2013, BMJ Supportive & Palliative Care.
[23] J. Coebergh,et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. , 2011, European journal of cancer.
[24] J. Suls,et al. The symptom perception hypothesis revised: depression and anxiety play different roles in concurrent and retrospective physical symptom reporting. , 2011, Journal of personality and social psychology.
[25] M. Dodd,et al. The effect of symptom clusters on functional status and quality of life in women with breast cancer. , 2010, European journal of oncology nursing : the official journal of European Oncology Nursing Society.
[26] D. Pud,et al. The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes. , 2008, Journal of pain and symptom management.
[27] J. Coebergh,et al. Increased health care utilization among long‐term cancer survivors compared to the average Dutch population: A population‐based study , 2007, International journal of cancer.
[28] F. Rodríguez‐Artalejo,et al. Gender differences in the utilization of health-care services among the older adult population of Spain , 2006, BMC public health.
[29] L. Frostholm,et al. The Patients’ Illness Perceptions and the Use of Primary Health Care , 2005, Psychosomatic medicine.
[30] M. Liang,et al. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. , 2003, Arthritis and rheumatism.
[31] J. Robbins,et al. Gender differences in the utilization of health care services. , 2000, The Journal of family practice.
[32] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.